Advanced Search Results
Search results for diagnosing bribery risk
Corruption within the pharmaceutical and healthcare sectors is a matter of life and death. It has a corrosive impact on health, negatively impacting public health budgets, the price of health services and medicines, and ultimately the quality of care dispensed. Reports estimate that as much as 6% of annual global health expenditure is lost to corruption
Incentivising Ethics: Managing Incentives to Encourage Good and Deter Bad Behaviour (October 2016) Managing Third Party Risk: Only as Strong as Your Weakest Link (June 2016) Wise Counsel or Dark Arts? Principles and Guidance for Responsible Corporate Political
The Government announced last year that it would publish its first-ever National Anti-Corruption Action Plan. Since TI first proposed this idea five years ago, we have been arguing that the Government should draw up such a plan, and we are delighted that it is now happening.
Robert Barrington and Will Kenyon discuss some of the challenges facing companies and why conducting an effective bribery risk assessment is necessary.
In the past few days, we have seen two high-profile corruption stories emanating from China – the allegations against GlaxoSmithKline (GSK) and the indictment of high-profile regional governor Bo Xilai. What should we make of them?